The ruxolitinib effect: understanding how molecular pathogenesis and epigenetic dysregulation impact therapeutic efficacy in myeloproliferative neoplasms
Crossref DOI link: https://doi.org/10.1186/s12967-018-1729-7
Published Online: 2018-12-17
Published Print: 2018-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Greenfield, Graeme http://orcid.org/0000-0003-2333-1374
McPherson, Suzanne
Mills, Ken
McMullin, Mary Frances
Text and Data Mining valid from 2018-12-01
Article History
Received: 1 November 2018
Accepted: 5 December 2018
First Online: 17 December 2018